BMO Capital downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform with a price target of $9.00 (from $18.00) following the resignation of the company's R&D President Sumant Ramachandra.
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $9.37 yesterday, with a 52 week range of $3.57-$11.88.